Catalent has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics, Inc. (Nasdaq: ACOR), a developer of therapies to restore function and improve the lives of people with neurological disorders.

Novan today announced an agreement with Catalent for the development of an intranasal formulation of berdazimer sodium for use in Novan’s COVID-19 program.

Catalent today announced the appointment of Nakaya “Nick” Matsumaru as General Manager of its new clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Passage Bio, Inc. and Catalent today announced that manufacturing operations have commenced to support adeno-associated virus (AAV) production for Passage Bio’s lead gene therapy product candidates for the treatment of rare monogenic CNS disorders.

Catalent today announced that it is investing $10 million in isolator capabilities at its sites in Malvern, Pennsylvania and Dartford, U.K., to expand its micronization capabilities for highly potent drug compounds.

Catalent today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib).

Catalent appoints Behzad Mahdavi, Ph.D., MBA, as Vice President of Open Innovation, Biologics, Cell and Gene Therapy. Dr. Mahdavi will join a team of experts to accelerate the adoption of new development and drug delivery technologies, and scalable manufacturing processes and techniques.

Catalent has completed the acquisition of Bone Therapeutics’ cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA (SCTS), including all of its assets located in Gosselies, Belgium.

Taysha Gene Therapies and Catalent today announced a partnership to support the development and manufacturing of Taysha’s gene therapies at Catalent’s Maryland-based gene therapy facilities.